Rivia, a Zurich-based software development company focused on AI-driven clinical trial data infrastructure, has raised an oversubscribed $15 million Series A funding round, according to an announcement shared on the company’s LinkedIn page. The round was led by Earlybird Venture Capital, with participation from Defiant, and continued backing from Speedinvest, Amino Collective, and Nina Capital. The funding marks a significant milestone for the company as it continues building a data engine designed to power clinical trial intelligence.
Rivia’s platform is built to address the complexity of modern clinical trials, which often involve fragmented systems, growing data volumes, and increasing regulatory scrutiny. By creating a unified data layer and ontology-driven infrastructure, the company enables biotech customers to run global trials more efficiently and derive earlier insights into patient outcomes.
Over the past two years, Rivia has supported biotech companies in executing clinical trials globally, helping identify potential issues that could lead to costly delays and enabling earlier clarity on which patients benefit most from treatments. The company’s system continues to improve as more trials are conducted, with its ontology library compounding over time to enhance performance and insights.
With the new funding, Rivia plans to expand its capabilities by scaling workflows and deploying AI-driven agents within clinical processes, aiming to reduce reliance on incremental human effort and improve the speed and precision of trial execution.
The LinkedIn post also notes that a full press release is available via a link in the comments, indicating that additional official details may be accessible through the company’s social channels.
KEY QUOTE:
“Big news from the Rivia team! We’ve raised an oversubscribed $15M Series A, led by Earlybird Venture Capital, alongside Defiant and continued support from Speedinvest, Amino Collective, and Nina Capital. This is a major milestone and an important step in building the data engine powering the future of clinical trial intelligence. Over the past two years, we’ve seen biotechs run global trials on Rivia and deliver measurable results, from preventing issues that would’ve cost millions to gaining earlier clarity on which patients benefit most. With every new trial, our ontology library compounds, making our system more powerful over time. Our goal is now to help clinical trials scale through workflows and AI rather than incremental human effort. To our customers, thank you for your trust and for pushing us every day. Your ambition and feedback shape everything we build. To the Rivia team, thank you for the intensity, ownership, and craft you bring every day.”
Rivia, Company LinkedIn Post
